Phase II trial of AVN 322 in patients with Alzheimer's disease.

Trial Profile

Phase II trial of AVN 322 in patients with Alzheimer's disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2013

At a glance

  • Drugs AVN 322 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Avineuro Pharmaceuticals
  • Most Recent Events

    • 27 Jun 2013 Status changed from planning to discontinued.
    • 09 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top